MAP3K1 and breast cancer: Interestingly, evidence suggests that these mutations in MAP3K1 and PIK3CA may provide a cooperative benefit to luminal breast cancer cells via enforced PI3K‐AKT signaling (Avivar‐Valderas et al, 2018).